Search
Lexicon Pharmaceuticals Inc
LXRXAdd to Watchlist
1.820USD
0.0000.00%
Close 10-02 16:00（ET）
808.44MMarket Cap
LossP/E TTM
Lexicon Pharmaceuticals Inc (LXRX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Lexicon Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
2 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
4.547USD+149.82%
LXRX Analyst Recommendation Trends
In the current month, LXRX has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LXRX average Analyst price target in the last month is 4.547.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
LXRX Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, LXRX EPS is projected to reach -0.058 in FY2026Q3, following reported EPS of -0.073 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.07
-0.03
-0.05
-0.06
-0.04
Actual
-0.04
-0.00
-0.07
--
--
Surprise
+38.07%
+92.41%
-44.62%
--
--
FAQs
What is Lexicon Pharmaceuticals Inc's expected revenue for the next quarter?
Lexicon Pharmaceuticals Inc's expected revenue is 4.14M.
What is Lexicon Pharmaceuticals Inc's price target?
Analysts forecast that Lexicon Pharmaceuticals Inc's price target is USD 4.55, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.00.
How have Lexicon Pharmaceuticals IncLXRX's recent earnings per share performed?
The market expectation was USD -0.07, while Lexicon Pharmaceuticals IncLXRX's earnings per share (EPS) for the previous quarter was USD -0.00. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for Lexicon Pharmaceuticals Inc?
Based on the ratings of Lexicon Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.